BPC-157 and TB-500 are the two most frequently compared peptides in tissue-repair research. They are studied for overlapping questions, which is why they are often paired – but they originate from different biology and the published work describes different mechanisms.
- BPC-157
- Gastric-derived pentadecapeptide
- TB-500
- Thymosin beta-4 fragment
- Shared research area
- Tissue repair
- Blend available
- Yes – studied together
The short answer
BPC-157 and TB-500 are studied for tissue repair from complementary angles. BPC-157 is a pentadecapeptide – fifteen amino acids – derived from a sequence found in gastric juice, and published work centres on angiogenic and gastrointestinal models. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein, and published work centres on actin binding and cell migration. Different origins, different described mechanisms, overlapping research interest.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Sequence from gastric juice | Fragment of thymosin beta-4 |
| Length | 15 amino acids | Short synthetic fragment |
| Mechanism studied | Angiogenic signalling, GI models | Actin binding, cell migration |
| Dominant study model | Rodent | Rodent and cell |
| Human trial data | Limited | Limited |
BPC-157: gastric origin, angiogenic focus
BPC-157 is derived from a protein sequence identified in gastric juice. Published research is dominated by rodent models, with a substantial share examining gastrointestinal tissue and vascular signalling. Its stability in gastric conditions is one of the properties that drew research attention to the sequence originally.
TB-500: a thymosin beta-4 fragment
TB-500 corresponds to an active region of thymosin beta-4, a protein present across many tissue types. The published mechanistic interest is in actin binding and the cell-migration processes that depend on it – a different route into repair biology from the angiogenic focus of the BPC-157 literature.
Why they are blended
The Wolverine Blend listing (BPC-157 + TB-500) exists because the two are studied from complementary angles rather than because their effects are known to add together. Research interest in the pairing follows from the mechanistic difference described above.
What the evidence does and does not show
Both compounds have limited published human trial data. The literature for each is weighted heavily toward rodent and cell models, and findings in those models do not automatically transfer. Claims that either compound produces a specific outcome in people are not supported by the published record.
All compounds referenced here are supplied as analytical-grade reference materials for in-vitro and laboratory research only. Nothing on this page is a recommendation for human or veterinary use, and no comparison below should be read as ranking these materials for any personal outcome.
Studies cited
- BPC-157 peptide: medical applications — literature & patent review (Pharmaceuticals (Basel, Switzerland), 2025)
- BPC-157 and musculoskeletal soft-tissue healing (Cell and tissue research, 2019)
- BPC-157 in orthopaedic sports medicine — systematic review (HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025)
- Beta-thymosins — overview (Annals of the New York Academy of Sciences, 2007)
- Thymosin beta-4 in regenerative therapy research (International immunopharmacology, 2023)
- Thymosin beta-4 and the eye (Expert opinion on biological therapy, 2018)
Questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a fifteen-amino-acid peptide derived from a sequence found in gastric juice, studied mainly in angiogenic and gastrointestinal rodent models. TB-500 is a synthetic fragment of the protein thymosin beta-4, studied mainly for actin binding and cell migration. They share a research area but not a mechanism.
Why are BPC-157 and TB-500 sold together as a blend?
BPC-157 and TB-500 are studied for tissue repair from complementary angles – different origins and different described mechanisms – which is the reason the two appear together as a single blended research listing.
Is TB-500 the same as thymosin beta-4?
TB-500 is not the full protein. It corresponds to an active region of thymosin beta-4, supplied as a shorter synthetic fragment rather than the complete naturally occurring protein.
Is there human trial data for BPC-157 or TB-500?
Published human trial data for both BPC-157 and TB-500 is limited. The literature for each is weighted heavily toward rodent and cell-model studies, and results in those models do not automatically transfer to humans.
For laboratory research and educational purposes only. Not medical advice. The materials discussed are not for human or animal consumption and have not been evaluated by the FDA.